Stifel Lifts PT on Insmed Incorporated (INSM) to $208 From $205 – Here’s Why

Insmed Incorporated (NASDAQ:INSM) is one of the best high growth healthcare stocks to buy now. Stifel raised the price target on Insmed Incorporated (NASDAQ:INSM) to $208 from $205 on March 24, reaffirming a Buy rating on the shares. The firm told investors that it believes Phase 3b ENCORE results “should unequivocally establish” Arikayce as the new first-line standard-of-care therapy to treat lung infection caused by nontuberculous mycobacteria-mycobacterium avium complex. It added that the ENCORE results “appear a best-case scenario for Arikayce label expansion efforts.”

Insmed (INSM) Soars After Raising $650 million

Insmed Incorporated (NASDAQ:INSM) reported full-year 2025 total revenues of $606.4 million, including BRINSUPRI revenues of $172.7 million for the year and $144.6 million in Q4. ARIKAYCE delivered $119.2 million in Q4 and $433.8 million for the full year, representing 19% annual growth and exceeding the upper end of guidance. The combination of accelerating commercial uptake and expanding market opportunity suggests that 2026 could mark a pivotal inflection point in revenue visibility and operating leverage.

Insmed Incorporated (NASDAQ:INSM) was founded in 1988. Headquartered in Bridgewater, New Jersey, Insmed is a global biopharmaceutical firm focused on developing and commercializing therapies for patients with rare and serious diseases, with key assets including brensocatib and Treprostinil Palmitil Inhalation Powder.

While we acknowledge the risk and potential of INSM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INSM and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.